InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Discover the full record of transactions filed by McMillan Wayde D., Chief Financial Officer. Director active across 2 companies, notably INSULET CORP. In total, 12 disclosures have been recorded. Breakdown: 0 buy · 3 sells. Total volume traded: €453k. History available since 31 December 2021. The latest transaction was filed on 13 May 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
9,503 shares0Common StockSEC:0001768648-26-000005:0
9,503 shares0Common StockSEC:0001768648-26-000005
1,455 shares@ US$275.600.0035% mcap49.6% of flowCommon StockSEC:0001127602-22-011546:0
2,361 shares0Common StockSEC:0001127602-22-007729:0
522 shares@ US$262.370.0012% mcap16.7% of flowCommon StockSEC:0001127602-22-007009:0
7,057 shares0Common StockSEC:0001127602-22-006035:0
153 shares@ US$240.810.0003% mcap4.4% of flowCommon StockSEC:0001127602-22-005765:0
153 shares@ US$240.810.0003% mcap26.3% of flowCommon StockSEC:0001127602-22-005765
205 shares@ US$252.810.0004% mcap6.2% of flowCommon StockSEC:0001127602-22-004559:0
205 shares@ US$252.810.0004% mcap36.8% of flowCommon StockSEC:0001127602-22-004559
193 shares@ US$266.370.0004% mcap36.9% of flowCommon StockSEC:0001127602-22-000457
193 shares@ US$266.370.0004% mcap6.2% of flowCommon StockSEC:0001127602-22-000457:0
12 of 12 declarations
About McMillan Wayde D.
Wayde D. McMillan is the CFO and Executive Vice President at Insulet Corp and Solventum Corp. In this role, he is responsible for the financial management of the companies, including financial planning, risk management, and financial reporting. His experience in the medical and technology sectors allows him to provide valuable expertise to support the companies' growth. He plays a key role in developing the financial strategy for the firms.
